2 researched Pharma entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Architect pharma and life sciences revenue operations in 2027 as a HCP-plus-payer-plus-IDN three-buyer GTM owned by a Chief Commercial Officer (CCO) with a co-equal VP of HCP/Field Sales, a VP of Market Access (payer + PBM), a…
Read full answer ↗Direct Answer Sentynl's 2026 fix abandons the "single-indication rare-disease drug as cash-drain" positioning and locks three defensible revenue engines: (1) Outcome-locked NULIBRY-market-penetration-to-revenue contracts bundled with Chief …
Read full answer ↗